Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Total Current Liabilities: 2015-2025

Historic Total Current Liabilities for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $61.8 million.

  • Editas Medicine's Total Current Liabilities fell 14.62% to $61.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.8 million, marking a year-over-year decrease of 14.62%. This contributed to the annual value of $77.2 million for FY2024, which is 22.16% up from last year.
  • Per Editas Medicine's latest filing, its Total Current Liabilities stood at $61.8 million for Q3 2025, which was down 6.32% from $65.9 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Total Current Liabilities ranged from a high of $77.2 million in Q4 2024 and a low of $36.4 million during Q2 2022.
  • Over the past 3 years, Editas Medicine's median Total Current Liabilities value was $65.9 million (recorded in 2025), while the average stood at $65.9 million.
  • As far as peak fluctuations go, Editas Medicine's Total Current Liabilities plummeted by 44.83% in 2022, and later skyrocketed by 56.58% in 2023.
  • Editas Medicine's Total Current Liabilities (Quarterly) stood at $46.9 million in 2021, then increased by 28.21% to $60.1 million in 2022, then climbed by 5.17% to $63.2 million in 2023, then rose by 22.16% to $77.2 million in 2024, then declined by 14.62% to $61.8 million in 2025.
  • Its last three reported values are $61.8 million in Q3 2025, $65.9 million for Q2 2025, and $73.1 million during Q1 2025.